NB Power explores feasibility and economic benefits of medical isotope harvesting at PLNGS

2026-02-05

FREDERICTON (NB) – NB Power is exploring the potential production of radioisotopes at the Point Lepreau Nuclear Generating Station (PLNGS).

Canada is a global leader in the production of radioisotopes for both medical and industrial use, and PLNGS would join a number of Canadian nuclear facilities currently active in the industry.

“At NB Power, our priority is using our expertise to make a meaningful difference in people’s lives,” said Lori Clark, President and CEO. “The potential production of medical radioisotopes at Point Lepreau represents an opportunity to support cancer diagnosis and treatment around the world. By leveraging the CANDU 6 reactor’s capabilities, we can contribute to global health care while continuing to serve New Brunswickers safely and responsibly.”

NB Power is continuing to seek innovative opportunities that add value for New Brunswickers. The CANDU 6 reactor design at the Point Lepreau Nuclear Generating Station is well-suited for the production of cancer-fighting medical radioisotopes, strategically enabling us to integrate this technology into our existing operations efficiently. In addition to supporting health and innovation, this initiative could also open up a new revenue stream, contributing to the utility’s long-term financial sustainability.

The technology being explored for potential integration at PLNGS is similar to what’s being used successfully at other Canadian CANDU reactors. Following the exposure, the material would be removed, packaged and shipped to a processing facility where it would undergo purification before being prepared for use. Potential uses of the harvested isotopes include prostate cancer treatment as well as diagnostic imaging.

As part of its assessment of a radioisotope production project, NB Power will be exploring opportunities with potential partners and completing feasibility studies and regulatory requirement activities.

NB Power has established an isotope team, composed of existing staff, to develop a conceptual strategic plan as well as lead the development of business and commercial agreements. The utility will work to create partnerships and is exploring various commercial agreement models, including funding opportunities for required installation and modifications of needed infrastructure. Full costs associated with the initiative will be determined as the exploration work continues.

“Medical isotopes save lives,” said Steve Bagshaw, PLNGS Site Vice President & Chief Nuclear Officer. “Most everyone knows a family member or friend that has been touched by cancer. Pursuing medical isotope harvesting at Point Lepreau to support lifesaving treatments is a significant opportunity for Canadians and for global health care while also offering potential revenue and economic benefits for New Brunswick.”

Any necessary modifications and installation of required infrastructure at PLNGS to support this new technology would be carried out during scheduled maintenance outages.

The continued operation of the station will continue to uphold the highest standards of safety, guided by rigorous nuclear regulations. These measures are in place to ensure the ongoing protection of NB Power employees, the public and the environment.

A fact sheet on isotope production is available here.

Media Contact:

Elizabeth Fraser - EFraser@nbpower.com